PRESS-RELEASE ·Filed Mar 2, 2026

EVAX

Evaxion
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release: announcement
Actionable Insight • Neutral

Traders should prepare for potential volatility following the March 5 earnings release. Monitor the upcoming financial results for revenue, cash runway, and R&D spend, which will be critical for assessing the company's development trajectory.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
EVAX ▲ +29.65% at T+60d
NEUTRAL call ✓ call won +29.65% · α vs SPY +20.33% · entry $3.17 → $4.11
Entry anchored
Feb 27, 03:59 PM ET
via exchange tick
T+1d
-1.58%
call -1.58% · α -0.66%
$3.12
settled 7mo ago
T+5d
-2.84%
call -2.84% · α -1.63%
$3.08
settled 7mo ago
T+20d
+18.93%
call +18.93% · α +26.87%
$3.77
settled 6mo ago
T+60d
+29.65%
call +29.65% · α +20.33%
$4.11
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Evaxion announced it will release its full-year 2025 financial results and provide a business update on March 5, 2026, followed by a conference call. The press release contains no financial data or material operational updates, only logistical details for the upcoming earnings event.

Key Facts

  • Evaxion will report full-year 2025 financial results on March 5, 2026, before Nasdaq opens.
  • Management will host a conference call and webcast the same day at 08:30 EST / 14:30 CET.
  • No financial results, guidance, or material business updates were disclosed in this announcement.
  • The release includes forward-looking statements and risk disclosures typical of public biotech companies.

Financial Impact

No financial impact from this announcement alone — no data disclosed.

Risk Factors

  • Low liquidity and high volatility risk due to small market cap ($26M).
  • Forward-looking statements suggest significant risks around funding, clinical development, and regulatory pathways.
  • No financials or updates provided — actual results could surprise to the upside or downside.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247291
36 reports for EVAX
Performance horizon
100% Hit rate 9 of 9 directional calls best @ T+5▲ +22.94%Mar 5, 2026
Filters
Rows
Reports for EVAX — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$3.07 $3.21▲ +4.56%▲ +4.45%$3.20 (+4.23%)
Sep 4, 2026
28d ago
6-K
BEARISH ★ 5/10
$3.12 $3.07▲ +1.60%▲ +0.39%$3.20 (−2.56%)
Aug 20, 2026
6w ago
6-K
NEUTRAL ★ 4/10
$3.28 $3.15▼ −3.96%▼ −5.08%$3.20 (−2.44%)
Aug 20, 2026
6w ago
Press Release
NEUTRAL ★ 4/10
$3.28 $3.15▼ −3.96%▼ −5.08%$3.20 (−2.44%)
Aug 17, 2026
6w ago
6-K
NEUTRAL ★ 4/10
$3.13 $3.40▲ +8.63%▲ +9.82%$3.20 (+2.24%)
Aug 14, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$3.34 $3.31▼ −0.90%▲ +0.47%$3.20 (−4.19%)
Aug 14, 2026
7w ago
Press Release
NEUTRAL ★ 2/10
$3.34 $3.31▼ −0.90%▲ +0.47%$3.20 (−4.19%)
Jul 17, 2026
11w ago
6-K
BULLISH ★ 7/10
$3.08 $3.05▼ −0.81%▼ −0.13%$3.20 (+4.07%)
Jul 17, 2026
11w ago
Press Release
NEUTRAL ★ 4/10
$3.08 $3.05▼ −0.81%▼ −0.13%$3.20 (+4.07%)
Jul 13, 2026
11w ago
6-K
NEUTRAL ★ 3/10
$3.02 $3.08▲ +1.82%▲ +2.61%$3.20 (+5.96%)
Showing 10 of 36

US Market Status

Market Closed — Opens Mon (65h 23m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 2, 2026